Scotiabank analyst Sung Ji Nam last night initiated coverage of Myriad Genetics with an Outperform rating and $29 price target. Myriad is an advanced diagnostics company focused on genetic testing and precision medicine for applications across oncology, women’s health, and mental health, the analyst tells investors in a research note. The firm says the company has undergone a significant transformation over the last several years to optimize its product portfolio and operational capabilities and to refocus on accelerating its growth. The transformation initiatives have begun to bear fruit, but Myriad is still in the early stages of maximizing its sales growth potential as well as achieving sustainable profitability, contends Scotiabank. It sees “meaningful headroom” for the stock over the next 12 months.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
- Myriad Genetics announces collaboration with GSK
- Myriad Genetics launches new Universal Plus Panel for Foresight Carrier Screen
- Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
- Myriad Genetics Proposes Settlement in Shareholder Lawsuits